A recent joint efficacy analysis by the Anthracyclines in Early Breast Cancer (ABC) trials included 4242 women with HER2-negative BC, from the USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 controlled trials. Here, ERBB2 is linked to breast carcinoma.